40.02 USD
↘ 0.28 (0.70%)AT CLOSE (03:59 PM EDT)
Edgewise Therapeutics, Inc. Common Stock
EWTXNASDAQ • USD
39.48
↘ 0.55 (1.36%)
POST MARKET (AS OF 04:20 PM EDT)
Post Market
AS OF 04:20 PM EDT
39.48
↘ 0.55 (1.36%)
Market: OPEN
Edgewise Therapeutics, Inc. Common Stock (EWTX) trades at $39.48 per share. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Furthermore, EWTX is currently richly valued, trading at a premium to sector peers across key valuation metrics.
Technical & fundamental data as of Oct 6, 2026.
Open?$40.66
High?$41.03
Low?$39.34
Prev. Close?$40.30
Volume?1.3M
Avg. Volume?1.5M
VWAP?$40.02
Rel. Volume?0.90x
Bid / Ask
Bid?$34.02 × 100
Ask?$45.94 × 100
Spread?$11.92
Midpoint?$39.98
Valuation & Ratios
Market Cap?4.4B
Shares Out?108.6M
Float?78.1M
Float %?72.6%
P/E Ratio?N/A
P/B Ratio?9.77
EPS?-$1.82
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Employees
127
Market Cap
4.4B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-03-26
Address
1715 38TH ST
BOULDER, CO 80301
Phone: 720-262-7002
BOULDER, CO 80301
Phone: 720-262-7002
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?23
Short Sent.?34
Piotroski F-Score?0/9Weak
Altman Z-Score?80.79Safe
Confidence?52%Low
Short InterestHigh
Short % of Float?12.22%High
Short Interest?9.5M
Days to Cover?8.0
Free Float78.1M
Avg Daily Volume1.2M
Settlement Date2026-09-15
Financial Health
Current Ratio?24.24Strong
Quick Ratio?24.24Strong
Cash Ratio?3.72Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?9.77HIGH▾
Peers100
S&P19
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-19.9CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-44.0%WEAK▾
S&P3
ROA?-41.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-158834000
Enterprise Value?$4.3B
Fundamentals ratios updated end of day